Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients

Falciparum Malaria Clinical Trial

Official title:

A Phase III Comparative, Open-label, Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Mefloquine (250mg) Plus Artesunate (100mg) in Children & Adult Patients With Acute Falciparum Malaria

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00403260
• Other study ID #: SP-C-004-06
• Status: Completed
• Phase: Phase 3
• Start date: January 2007
• Est. completion date: December 2008

Study information

• Verified date: October 2021
• Source: Medicines for Malaria Venture
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this phase III clinical study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (Pyramax®, PA) with that of the combination of mefloquine plus artesunate (MQ + AS) in children and adults with uncomplicated P falciparum malaria in South East Asia, India and Africa.

Description:

This is a multi-centre, comparative, randomised, open-label, parallel-group, non-inferiority study comparing the efficacy and safety of a fixed combination of PA to a loose combination of MQ + AS for patients with acute, symptomatic, uncomplicated P. falciparum malaria. The study population will include 1271 patients, comprising male and female children (≥20 kg body weight) and adults, recruited from study sites in South East Asia, India and Africa. Patients will be randomised in a 2:1 ratio to receive either oral PA (180:60mg tablets) or MQ (250mg tablets) plus AS (100mg tablets) once a day for 3 consecutive days (Days 0, 1, and 2). The study drug will be administered by a Third-Party Investigator unblinded to the study treatment, while the Investigator remains blinded.

Patients will be confined to the to the study facility for ≥4 days (Days 0, 1, 2, and 3) and remain near the study site for ≥7 days, or once fever and parasite clearance has been confirmed for ≥24 hours - whichever occurs later.

The primary efficacy end point for the study is the proportion of patients with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28. Scheduled follow-up visits will continue until completion of the study at Day 42. In the case of adverse events reported and unresolved at Day 42, patients will be followed up for a further 30 days, or until resolution of the event.

The primary efficacy end point for the study is the proportion of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28 (defined as the absence of parasitaemia without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure). Scheduled follow-up visits will continue until completion of the study at Day 42. In the case of adverse events reported and unresolved at Day 42, patients will be followed up for a further 30 days, or until resolution of the event.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1271
• Est. completion date: December 2008
• Est. primary completion date: October 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 60 Years

Eligibility

Inclusion Criteria:

• Male or female patients between the ages of 3 and 60 years, inclusive.

• Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.

• Presence of acute uncomplicated P. falciparum mono-infection confirmed by:

1. Fever, as defined by axillary/tympanic temperature =37.5°C or oral/rectal temperature =38°C, or documented history of fever in the previous 24 hours and,

2. Positive microscopy of P. falciparum with parasite density between 1,000 and 100,000 asexual parasite count/µl of blood

• Written informed consent provided by patient and/or parent/guardian/spouse.

• Ability to swallow oral medication.

Exclusion Criteria:

• Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organization Criteria 2000.

• Mixed Plasmodium infection.

• Severe vomiting or severe diarrhoea.

• Known history or evidence of clinically significant disorders.

• Presence of significant anaemia, as defined by Hb <8 g/dL.

• Presence of febrile conditions caused by diseases other than malaria.

• Known history of hypersensitivity, allergic or adverse reactions to pyronaridine, mefloquine or artesunate or other artemisinins.

• Use of any other antimalarial agent within 2 weeks prior to start of the study as evidenced by positive urine test.

• Female patients of child-bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures to not become pregnant during the study period.

• Presence of significant renal or hepatic impairment.

• Receipt of an investigational drug within the past 4 weeks.

• Known active Hepatitis A IgM, Hepatitis B surface antigen or Hepatitis C antibody.

• Known seropositive HIV antibody.

• Previous participation in any clinical study with PA.

Related Conditions & MeSH terms

• Falciparum Malaria
• Malaria
• Malaria, Falciparum

Intervention

Drug:
• Pyronaridine - artesunate
once a day for 3 days
• Mefloquine plus artesunate
once a day for 3 days

Locations

Country	Name	City	State
Burkina Faso	RAOTAP2/Centre Muraz	Bobo Dioulasso	Houet Province
Cambodia	Pailin Referral Hospital	Pailin	Pailin Province
Côte D'Ivoire	Institut Pasteur	Abidjan
India	Wentlock District Hospital	Mangalore
Tanzania	Bagamoyo Research and Training Centre of Ifakara Health Institute	Bagamoyo
Thailand	MaeLamad District Hospital	Mae Ramat	Tak Province
Thailand	MaeSod General Hospital	Mae Sot	Tak Province
Vietnam	NIMPE	Hanoi	Commune Xy
Vietnam	Choray Hospital, Dak O	Ho Chi Minh City

Sponsors (2)

Lead Sponsor	Collaborator
Medicines for Malaria Venture	Shin Poong Pharmaceuticals

Countries where clinical trial is conducted

Burkina Faso,  Cambodia,  Côte D'Ivoire,  India,  Tanzania,  Thailand,  Vietnam, 

References & Publications (1)

Rueangweerayut R, Phyo AP, Uthaisin C, Poravuth Y, Binh TQ, Tinto H, Pénali LK, Valecha N, Tien NT, Abdulla S, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L; Pyronaridine-Artesunate Study Team. Pyronaridine-artesunate versus mefloquine plus artesun — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Subjects With PCR-corrected Adequate Clinical and Parasitological Response (ACPR) on Day 28	Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure.	Day 28
Secondary	PCR-corrected ACPR on Day 14	Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure	Day 14
Secondary	Crude ACPR on Days 14 and 28	Percentage of subjects with adequate clinical and parasitological response (ACPR) on Days 14 and 28, without correction by PCR, defined as absence of parasitaemia on Days 14 and 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure	Days 14 and 28
Secondary	Parasite Clearance Time	Parasite clearance time was defined as the time from first dosing to time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.	Thick blood films were examined every 8 hours until =72 hours or until 2 consecutive negative readings occurred 7 to 25 hours apart, and on Days 3, 7, 14, 21, 28, 35, and 42 (or any other day if the subject returned).
Secondary	Fever Clearance Time	Fever clearance time was defined as the time from first dosing to first normal reading of temperature (<37.5°C taken axillary or tympanic; <38°C taken oral or rectal) for 2 consecutive normal temperature readings taken between 7 and 25 hours apart.	Every 8 hours over =72 hours following first study drug administration or temperature normalisation for =2 readings between 7 and 25 hours apart, then at each visit.
Secondary	Parasite Clearance at Day 1, 2 and 3	Parasite clearance time was defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart.	Days 1, 2 and 3
Secondary	Fever Clearance at Day 1, 2 and 3	Fever clearance time was defined as the time for at least 2 consecutive normal body temperature measurements (<37.5°C axillary/tympanic or <38.0°C oral/rectal) to be obtained within an interval of 7 to 25 hours post-dosing.	Days 1, 2 and 3
Secondary	Adverse Events and Clinically Significant Laboratory Results	Cases and severity of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities	Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier

External Links

•   Medicines for Malaria Venture